We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: Celyad Oncology (Euronext: CYAD) (la “Société”), annonce aujourd'hui la présentation de deux posters lors de la 39e réunion annuelle de la Society for Immunotherapy of Cancer...
MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with...
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...
MONT-SAINT-GUIBERT, Belgium, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the...
MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK...
MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of...
MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance...
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the...
MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.082 | 12.0588235294 | 0.68 | 0.85 | 0.637 | 84756 | 0.73731465 | DE |
4 | 0.393 | 106.504065041 | 0.369 | 1.22 | 0.3325 | 209592 | 0.79187257 | DE |
12 | 0.537 | 238.666666667 | 0.225 | 1.22 | 0.225 | 84009 | 0.68971792 | DE |
26 | 0.469 | 160.068259386 | 0.293 | 1.22 | 0.212 | 46087 | 0.61460424 | DE |
52 | 0.382 | 100.526315789 | 0.38 | 1.22 | 0.212 | 36862 | 0.5270561 | DE |
156 | -2.888 | -79.1232876712 | 3.65 | 4.6 | 0.212 | 40721 | 1.37650815 | DE |
260 | -10.378 | -93.1597845601 | 11.14 | 12.08 | 0.212 | 42382 | 3.70305013 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions